Cargando…

Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)

INTRODUCTION: Tumor necrosis factor (TNF) and, possibly, lymphotoxin alpha (LTα) signaling contribute to inflammation and rheumatoid arthritis (RA) pathogenesis. Pateclizumab (anti-lymphotoxin- alpha; MLTA3698A) is a humanized monoclonal antibody that blocks and depletes anti-LTα. This phase 2, rand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kennedy, William P, Simon, J Abraham, Offutt, Carolyn, Horn, Priscilla, Herman, Ann, Townsend, Michael J, Tang, Meina T, Grogan, Jane L, Hsieh, Frank, Davis, John C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243296/ https://www.ncbi.nlm.nih.gov/pubmed/25359150 http://dx.doi.org/10.1186/s13075-014-0467-3

Ejemplares similares

Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial
por: Emu, Brinda, et al.
Publicado: (2012)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
por: Weinblatt, Michael E, et al.
Publicado: (2013)

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Lymphotoxin α revisited: general features and implications in rheumatoid arthritis
por: Calmon-Hamaty, Flavia, et al.
Publicado: (2011)

Lymphotoxin-LIGHT Pathway Regulates the Interferon Signature in Rheumatoid Arthritis
por: Bienkowska, Jadwiga, et al.
Publicado: (2014)

Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs
por: Favalli, Ennio Giulio, et al.
Publicado: (2014)

Genomic organization and phylogenetic utility of deer mouse (Peromyscus maniculatus) lymphotoxin-alpha and lymphotoxin-beta
por: Richens, Tiffany, et al.
Publicado: (2008)

Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
por: Best, Jennie H., et al.
Publicado: (2020)

Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial
por: Wei, James Cheng-Chung, et al.
Publicado: (2020)

In Vivo Depletion of Lymphotoxin-Alpha Expressing Lymphocytes Inhibits Xenogeneic Graft-versus-Host-Disease
por: Chiang, Eugene Y., et al.
Publicado: (2012)

Lymphotoxin-sensitive microenvironments in homeostasis and inflammation
por: Boulianne, Bryant, et al.
Publicado: (2012)

RANKL expression in chondrocytes and its promotion by lymphotoxin-α in the course of cartilage destruction during rheumatoid arthritis
por: Takeshita, Ayumu, et al.
Publicado: (2021)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca, Giuseppe, et al.
Publicado: (2013)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study
por: Gottlieb, A.B., et al.
Publicado: (2021)

Chronic inflammation caused by lymphotoxin is lymphoid neogenesis
Publicado: (1996)

Lymphotoxin expression in human and murine renal allografts
por: Seeger, Harald, et al.
Publicado: (2018)

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
por: Capsoni, Franco, et al.
Publicado: (2005)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Sweet’s Syndrome in a Patient With Seropositive Rheumatoid Arthritis After Starting Adalimumab: Is Sweet’s Syndrome Related to Rheumatoid Arthritis or Is It the Paradoxical Effect of Adalimumab?
por: Paul, Prodip, et al.
Publicado: (2021)

The Tumor Necrosis Factor Superfamily Members TNFSF14 (LIGHT), Lymphotoxin β and Lymphotoxin β Receptor Interact to Regulate Intestinal Inflammation
por: Giles, Daniel A., et al.
Publicado: (2018)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin
Publicado: (1984)

A Critical Role for Lymphotoxin in Experimental Allergic Encephalomyelitis
por: Suen, Winnie E., et al.
Publicado: (1997)

Lymphotoxin, but Not TNF, Is Required for Prion Invasion of Lymph Nodes
por: O'Connor, Tracy, et al.
Publicado: (2012)

Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγ(null) mice reconstituted with human peripheral blood mononuclear cells
por: Jodeleit, Henrika, et al.
Publicado: (2021)

HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA
por: Rigby, William, et al.
Publicado: (2021)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis
por: Nguyen, Dao X., et al.
Publicado: (2018)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study
por: Eng, Grith P., et al.
Publicado: (2015)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study
por: Ortea, Ignacio, et al.
Publicado: (2016)

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Secreted Lymphotoxin-α Is Essential for the Control of an Intracellular Bacterial Infection
por: Roach, Daniel R., et al.
Publicado: (2001)

The Requirement of Membrane Lymphotoxin for the Presence of Dendritic Cells in Lymphoid Tissues
por: Wu, Qiang, et al.
Publicado: (1999)

The Sequential Role of Lymphotoxin and B Cells in the Development of Splenic Follicles
por: Gonzalez, Mercedes, et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_4efge4marampuq0b6d74n605rv